EUVIMEDOpdag EUVIMED
Crossref

Immunomodulation by juglone alleviates acute graft‐versus‐host disease without compromising the graft‐versus‐leukaemia activity in mice

Dievya Gohil, Khushboo A Gandhi, Saurabh Kumar Gupta, Poonam Gera, Subhash Yadav, Raghavendra Patwardhan, Rahul Checker, Deepak Sharma, Navin Khattry, Santosh Sandur, Vikram Gota iD

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.16350 ↗

At a glance

Journal article in British Journal of Pharmacology, 2026. Written by Dievya Gohil and 10 co-authors. Institution: Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India. Major MEDLINE topics: Graft vs Host Disease, Naphthoquinones, Immunomodulating Agents. Cited 1 times so far (Crossref); 79 references. Funded by: Indian Council of Medical Research.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Acute graft‐versus‐host disease (GVHD) remains a major barrier to successful transplantation outcomes. Recent studies have shown that pharmacotherapy for GVHD should target both the innate and adaptive inflammatory immune responses. Juglone, a redox‐active phytochemical found in walnuts, has shown potent anti‐inflammatory effects in models of colitis and inflammatory bowel disease. However, its effects on T‐cell‐mediated immune responses remain largely unknown. Considering the overlapping mediators of inflammation in GVHD and the aforementioned conditions, we investigated the use of juglone as a prophylactic agent for GVHD. Experimental Approach Immunomodulatory activity and mechanism of action of juglone were studied using murine splenic leukocytes in vitro. The GVHD prophylactic efficacy of orally administered juglone was evaluated using a murine model of allogeneic haematopoietic stem cell transplantation based on an MHC mismatch. Key Results Juglone exhibited immunomodulatory activity by (i) inhibiting the activation of dendritic cells and CD4 + T‐cells, (ii) inhibiting cytokine secretion and lymphocyte proliferation, and (iii) inducing exhaustion of CD4 + T‐cells, as shown by increased expression of CTLA‐4 (CD152) and Fas (CD95). Oral administration of juglone significantly reduced mortality and morbidity associated with GVHD while maintaining graft‐versus‐leukaemia activity. This was accompanied by a decrease in the number of naïve CD4 + cells, and an increase in the number of CD4 + and CD8 + central memory T‐cells. Conclusion and Implications Juglone is a potent immunomodulator for GVHD prophylaxis. Our study is the first to provide a dosage framework for the oral administration of juglone that can be used for clinical development. LINKED ARTICLES This article is part of a themed issue Recent Innovations in Targeting Redox Biology for Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.1/issuetoc

Subjects

MeSH terms (MEDLINE)

Graft vs Host DiseaseNaphthoquinonesImmunomodulating AgentsAnimalsMiceMice, Inbred C57BLMice, Inbred BALB CHematopoietic Stem Cell TransplantationFemaleCD4-Positive T-LymphocytesMaleImmunomodulationCytokines

Author keywords

Nrf‐2cellular redoxgraft‐versus‐host diseasegraft‐versus‐leukaemiaimmunomodulationjuglone

Substances

NaphthoquinonesjugloneImmunomodulating AgentsCytokines

Authors and institutions

  • Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
  • Training School Complex, Homi Bhabha National Institute, Mumbai, India.
  • ICGC Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
  • Biorepository, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
  • Department of Pathology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
  • Radiation Biology & Health Science Division, Bio-science group, Bhabha Atomic Research Centre, Mumbai, India.

ORCID profiles: Vikram Gota

Funding

  • Indian Council of Medical Research

Cite

APA

Gohil, D., Gandhi, K. A., Gupta, S. K., Gera, P., Yadav, S., Patwardhan, R., Checker, R., Sharma, D., Khattry, N., Sandur, S., & Gota, V. (2026). Immunomodulation by juglone alleviates acute graft‐versus‐host disease without compromising the graft‐versus‐leukaemia activity in mice. British Journal of Pharmacology. https://doi.org/10.1111/bph.16350

Vancouver

Gohil D, Gandhi KA, Gupta SK, Gera P, Yadav S, Patwardhan R, et al. Immunomodulation by juglone alleviates acute graft‐versus‐host disease without compromising the graft‐versus‐leukaemia activity in mice. British Journal of Pharmacology. 2026. doi:10.1111/bph.16350

BibTeX
@article{Gohil2026,
  author = {Gohil, Dievya and Gandhi, Khushboo A and Gupta, Saurabh Kumar and Gera, Poonam and Yadav, Subhash and Patwardhan, Raghavendra and Checker, Rahul and Sharma, Deepak and Khattry, Navin and Sandur, Santosh and Gota, Vikram},
  title = {Immunomodulation by juglone alleviates acute graft‐versus‐host disease without compromising the graft‐versus‐leukaemia activity in mice},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.16350}
}
Start for free →